Teclistamab-cqyv is a Bispecific T-cell Engager (BiTE) immunotherapy that targets CD3, expressed on T cells, and the B-cell maturation antigen, which is highly expressed on malignant multiple myeloma plasma cells.
The drug is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have failed prior therapy.